Biofusion Therapeutics Limited
About Biofusion Therapeutics Limited
Data last updated:
Biofusion Therapeutics Limited was a public limited company based in Bengaluru, Karnataka, India, operated as a subsidiary of Biocon Limited. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It operated in the biotechnology segment of the life sciences sector. It was incorporated on 18 March 2021.
The company was registered with the Registrar of Companies (ROC), Bangalore, under CIN U73100KA2021PLC145487. Its GSTIN is 29AAJCB7258B1ZK (Karnataka).
The company had an authorised share capital of ₹15 Lakh and a paid-up capital of ₹5 Lakh. It was led by directors including Kiran Mazumdar Shaw and Siddharth Mittal.
Its last annual general meeting (AGM) was held on 11 August 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office was at Bengaluru, Karnataka.
As per the financials filed for FY 2023, the company reported a revenue of ₹56.53 Cr, a growth of 41% compared to the previous year. For the same year it recorded a net profit of ₹25.91 Cr (net margin 45.8%) and EBITDA of ₹40.42 Cr (EBITDA margin 71.5%).
The company had about 3 employees on its provident fund (EPFO) records before it was dissolved.
As per MCA filings, the company had satisfied charges of ₹42.71 Cr on record. Court records list 1 case involving the company, including 1 filed by the company.
Company details
Contact details
Biofusion Therapeutics Limited's registered office is in Bengaluru, Karnataka. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address4th Floor Pod2 Brc Building Biocon Special Economic Zone Bommasandra Industrial Ar, Ea, Bengaluru, Karnataka, India – 560099
- IndustryLife Sciences, Biotechnology
To see the full contact details of Biofusion Therapeutics Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Biofusion Therapeutics is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Biofusion Therapeutics Limited, buy the company report.
Financials of Biofusion Therapeutics Limited
FY 2023 filings availableBiofusion Therapeutics Limited reported revenue of ₹56.53 Cr (up 41% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue rose 41% in the latest year. EBITDA rose 274% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | ₹56.53 Cr | ||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | ₹40.42 Cr | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | ₹25.91 Cr | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | 71.5% | ||
| Net Profit Margin | 45.8% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Biofusion Therapeutics Limited, buy the company report.
Board of directors of Biofusion Therapeutics Limited
Biofusion Therapeutics has 3 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kiran Mazumdar Shaw | Director | 18 Mar 2021 | 5 Years 7 Months | As last reported |
| Siddharth Mittal Also directs: Syngene International Limited, Biocon Pharma Limited, Biocon Biosphere Limited and 1 more | Director | 18 Mar 2021 | 5 Years 7 Months | As last reported |
| Karaikal Narayanaswamy Murali Krishnan Also directs: Biocon Pharma Limited, Biocon Biosphere Limited | Director | 27 Jul 2022 | 4 Years 2 Months | As last reported |
Auditor
Biofusion Therapeutics Limited is audited by B S R & Co. LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| B S R & Co. LLP | FY 2023 | 101248W/W-100022 |
Shareholding
The shareholding of Biofusion Therapeutics Limited is on record for 2 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Biofusion Therapeutics Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 21 Apr 2022 | 100581935 | Citi Bank N.A. | ₹42.71 Cr | Satisfied |
To see the full charge records of Biofusion Therapeutics Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
Biofusion Therapeutics Limited has 1 court case on record: 1 filed by Biofusion Therapeutics. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| NCLT | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLT, Bengaluru | Court case (C.P.(CAA)) | Filed by the company | Disposed |
To see the full case history of Biofusion Therapeutics Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Biofusion Therapeutics Limited has 8 MSME Form 1 returns on record between 2021 and 2024, listing 206 overdue payments to 64 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 64)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Systech Softwares Private Limited | |||
| Immacule Lifesciences Private Limited | |||
| Suresh Surana & Associates LLP | |||
| Value Point Systems Private Limited | |||
| Ultra Lab Products |
To see the full MSME payment records of Biofusion Therapeutics Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Biofusion Therapeutics Limited has a workforce of 3 employees on its EPFO records as of Mar 29, 2024, across 1 active EPFO establishment.
GST
Biofusion Therapeutics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAJCB7258B1ZK | Karnataka | Active | 09 Jun 2021 |
To see the full GST registrations and return filing status of Biofusion Therapeutics Limited, buy the company report.
Recent activity
Biofusion Therapeutics Limited has 5 board changes on record since 2021: 3 appointments and 2 cessations. The latest: Karaikal Narayanaswamy Murali Krishnan ceased to be Additional Director on 10 Aug 2023.
Frequently asked questions
Biofusion Therapeutics has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.
Biofusion Therapeutics was a public limited company based in Bengaluru, Karnataka, India. The company worked in biotechnology, within the life sciences industry. It was incorporated on 18 March 2021 and is registered under CIN U73100KA2021PLC145487. The company is recorded as amalgamated in MCA records and no longer exists as a legal entity.
Biofusion Therapeutics was incorporated on 18 March 2021. It is registered with the Registrar of Companies, Bangalore.
Biofusion Therapeutics had 3 directors:
- Kiran Mazumdar Shaw - Director
- Siddharth Mittal - Director
- Karaikal Narayanaswamy Murali Krishnan - Director
The CIN (Corporate Identification Number) of Biofusion Therapeutics is U73100KA2021PLC145487. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Biofusion Therapeutics is at 4th Floor Pod2 Brc Building Biocon Special Economic Zone Bommasandra Industrial Ar, Ea, Bengaluru, Karnataka, India – 560099.
The latest financial statements of Biofusion Therapeutics on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 11 August 2023. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Biofusion Therapeutics is 29AAJCB7258B1ZK, registered in Karnataka.
Biofusion Therapeutics operated in the life sciences industry, in the biotechnology segment.
Biofusion Therapeutics has 8 MSME Form 1 returns on record between 2021 and 2024, listing 206 overdue payments to 64 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Biofusion Therapeutics has 1 court case on record: 1 filed by the company.